Clinical trials: Graves' Ophthalmopathy
Graves' Disease
Treatment of Graves' Hyperthyroidism With Selenium Plus Methimazole
Evaluation of the efficacy of the combined treatment (methimazole plus selenium) in the control of hyperthyroidism as compared to methimazole alone in 30 Graves' disease (GD) untreated patients.
- Trial name
- NCT02727738
- Testing
- Selenium, Methimazole
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Pisa
Graves' Disease
Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD)
This study will test an experimental Regeneron drug called REGN24493 hereby referred to as "study drug" to see if it can help treat Graves' disease.
- Trial name
- EMERGE (NCT07861152)
- Testing
- REGN24493
- Volunteers
- 45 people
- Sponsor
- Regeneron Pharmaceuticals
Thyroid Associated Ophthalmopathy
Construction and Application of Precise Diagnosis and Treatment System for Thyroid-associated Ophthalmopathy
This study aims to develop the deep learning-based system that integrates multimodal information to automatically diagnose, stage, and grade thyroid-associated ophthalmopathy (TAO), assist in treatment decision-making, and…
- Trial name
- NCT07124572
- Testing
- Imaging and ocular examinations
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Thyroid Eye Disease
Customized Multiple Orbital Wall Decompression for Sight-threatening Graves's Ophthalmopathy
Graves' orbitopathy (GO) is an disfiguring and disabling autoimmune condition. Sight-threatening GO is an most severe form and occurs in about 5% of patients with Graves' disease.
- Trial name
- NCT05627401
- Testing
- Modified multiple orbital wall decompression
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Graves Disease, Graves Ophthalmopathy
Liver Function After Intravenous Methylprednisolone Administration
Graves' orbitopathy (GO) is a characterized by orbital soft tissue inflammation and oedema associated with glycosaminoglycan deposition and fibrosis. The most frequent cause is Graves' disease.
- Conditions
- Graves Disease, Graves Ophthalmopathy, Liver Diseases, Liver Failure
- Trial name
- NCT03667157
- Testing
- every week IVMP therapy, very high doses IVMP therapy
- Volunteers
- 68 people
- Sponsor
- Medical University of Warsaw
Graves' Ophthalmopathy
The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy
The relationship between the method of the treatment of hyperthyroidism due to Graves' disease and the course of Graves' ophthalmopathy is debated.
- Trial name
- NCT01056419
- Testing
- Total Thyroidectomy, Propylthiouracil
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Ankara University
Graves Disease, Hyperthyroidism
Remission Induction and Sustenance in Graves' Disease 2
ATD therapy for Graves' disease is one of the commonly used options for therapy of the hyperthyroidism. The investigators study how to optimally keep patients in remission.
- Trial name
- NCT00796913
- Testing
- Stop medication
- Volunteers
- 139 people
- Sponsor
- Aalborg University Hospital
Autoimmune Hyperthyroidism, Children
Autoimmune Hyperthyroidism in Prepubertal Children
The investigators propose a multicenter retrospective study to assess clinical, biochemical, and auxological characteristics at diagnosis and during follow-up in a cohort of Caucasian pediatric patients diagnosed with autoimmune…
- Trial name
- IPER6 (NCT07544290)
- Testing
- restrospective observational study
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS Ospedale San Raffaele
Graves Ophthalmopathy, Graves Disease
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
The aim of this study is to evaluate the effects of subantimicrobial dose doxycycline (50 mg/d), administered for 12 wk, for patients with active moderate-severe Graves' Orbitopathy (GO).
- Conditions
- Graves Ophthalmopathy, Graves Disease, Eye Diseases, Thyroid Diseases
- Trial name
- NCT01727973
- Testing
- Doxycycline
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Sun Yat-sen University
Exophthalmos, Graves Ophthalmopathy
Exophthalmometry With 3D Face Scanners
This study investigates diagnostic methods to measure eyeball protrusion with a smartphone face scanner compared to the traditional Hertel exophthalmometer.
- Conditions
- Exophthalmos, Graves Ophthalmopathy, Orbital Tumor, Orbital Fractures
- Trial name
- EX3D (NCT04704414)
- Testing
- Exophthalmos measurement
- Where
- Switzerland
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Graves Disease
Effects of Vitamin D Supplementation on Muscle Function Among Grave's Disease Patients
Introduction: A deficit in vitamin D may be involved in the development and presentation of Graves' disease (GD). Lack of vitamin D and GD are linked to deteriorating quality of life (QoL) and weakening of the muscles.
- Trial name
- NCT06451016
- Testing
- Vitamin D supplements
- Where
- 2 sites in Pakistan
- Volunteers
- 48 people
- Sponsor
- Frontier Medical and Dental College, Abbotabad
Graves' Disease
A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease
This is a parallel group, Phase 2, 2-arm study to measure the treatment effect and safety of rilzabrutinib dose 1 or rilzabrutinib dose 2 in participants with Graves' disease, with and without Graves' orbitopathy, aged 18 years…
- Trial name
- NCT06984627
- Testing
- Rilzabrutinib dose 1, Rilzabrutinib dose 2
- Where
- 24 sites in Argentina, Canada and 7 more
- Volunteers
- 30 people
- Sponsor
- Sanofi
Graves' Disease
Randomized Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy
OBJECTIVES: I. Evaluate the effects of 20 Gy of external-beam radiotherapy to 1 orbit vs. the untreated orbit at 3 and 6 months after therapy in patients with Graves' ophthalmopathy. II.
- Trial name
- NCT00004660
- Testing
- Radiotherapy
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Graves Orbitopathy
Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy
The overall objective of the study is to evaluate the safety and efficacy of rabbit antithymocyte globulin in the treatment of Graves orbitopathy (GO) after ineffective treatment with moderate-to-high doses of glucocorticoids.
- Trial name
- NCT05199103
- Testing
- rabbit anti-thymocyte globulin
- Where
- Poland
- Volunteers
- 20 people
- Sponsor
- Medical University of Silesia
Thyroid Eye Disease
A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)
The investigational drug, veligrotug (VRDN-001), is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).
- Trial name
- THRIVE (NCT05176639)
- Testing
- Veligrotug
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 113 people
- Sponsor
- Viridian Therapeutics, Inc.
Graves´ Disease, Thyroid Associated Ophthalmopathy
Rituximab in the Treatment of Graves' Disease
Aim: In a phase II pilot study encompassing 20 patients with Graves' disease to evaluate the effect of rituximab: 1. Biochemically as assessed by markers of disease activity ( free T4, free T3, TSH, TSH-receptor antibodies…
- Trial name
- NCT00150111
- Testing
- Methimazole, Rituximab, Immunization with various vaccines
- Where
- 2 sites in Denmark
- Volunteers
- 20 people
- Sponsor
- Odense University Hospital
Thyroid Eye Disease, Graves Orbitopathy
A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)
Thyroid eye disease (TED) is a rare autoimmune, inflammatory disorder of the orbit and represents the most common extra-thyroidal manifestation of Graves' disease (GD).
- Trial name
- ORBIT (NCT04737330)
- Testing
- Secukinumab
- Where
- 5 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Thyroid Eye Disease, TED
Psychological Burden of Thyroid Eye Disease
This interview study aims to look in depth at the quality of life of people living with TED and their caregivers, with emphasis on impact on mood, relationships, work/education, and leisure.
- Trial name
- NCT07444190
- Testing
- focus groups and individual interviews as well as filling out questionnaires
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Thomas Jefferson University
Thyroid Eye Disease
B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease
Thyroid eye disease (TED) is an autoimmune inflammation of the orbital tissues that develops in up to 50% of patients with Graves' disease.
- Trial name
- BetTeRTED (NCT02316691)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Pittsburgh
Thyroid Eye Disease
Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)
Phase 1/2, multicenter, multiple dose clinical study designed to evaluate lonigutamab in subjects with TED.
- Trial name
- TED (NCT05683496)
- Testing
- lonigutamab
- Where
- 11 sites in United States, Australia
- Volunteers
- 31 people
- Sponsor
- ACELYRIN Inc.